Publications

Add filters (0)

13 results

Fibroblast activities are associated with prolonged QTc and pulmonary arterial hypertension in patients with systemic sclerosis.

March 12, 2025

Clin Exp Rheumatol

Abstract OBJECTIVES In systemic sclerosis patients (SSc), we aimed at exploring the potential of serum biomarkers of fibrosis and immune-cell activity to detect subclinical heart involvement determined by electrocardiographic (ECG) alterations. METHODS A panel of extracellular matrix (ECM) turnover biomarkers quantifying type III and VI collagen formation (PRO-C3 and PRO-C6), type IV collagen turnover (PRO-C4), […]

Read publication

Serological markers of basement membrane collagen type IV and laminin are increased in systemic lupus erythematosus but differentially expressed in patients with previous cardiovascular events.

November 1, 2023

Clin Exp Rheumatol

Abstract OBJECTIVES To assess basement membrane remodelling in systemic lupus erythematosus (SLE) by studying serum levels of type IV collagen (C4M) and laminin (LG1M) fragments and their association with disease profile. METHODS One hundred and six SLE patients without and 20 with previous cardiovascular events were included. One hundred and twenty male and female blood […]

Read publication

Differentiating patients with psoriasis from psoriatic arthritis using collagen biomarkers.

March 1, 2023

Clin Exp Rheumatol

Abstract OBJECTIVES Around 30% of patients diagnosed with cutaneous psoriasis (PsC) will go on to develop psoriatic arthritis (PsA) which includes inflammation of the joints. Collagens are core proteins in all tissues, which are involved in the inflammatory process in both PsC and PsA. The aim of this study is to investigate collagen biomarkers and […]

Read publication

Biochemical markers in osteoarthritis with lessons learned from osteoporosis.

October 1, 2019

Clin Exp Rheumatol

Abstract Osteoarthritis (OA) is a disease of the whole joint, including synovium, bone and cartilage. OA is a slow degenerative and very heterogeneous disease, with both varying levels of disease activity and progression. Biomarkers are urgently needed to assist drug developers in selecting and developing the projects with the highest chance of success. Biomarkers for […]

Read publication

Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis.

June 1, 2019

Clin Exp Rheumatol

Abstract OBJECTIVES Non-radiographic (nr-axSpA) and radiographic (AS) forms of axial spondyloarthritis (axSpA) share clinical features, but have different radiographic patterns. Radiographic progression is not associated with the current disease activity biomarkers. We investigated a matrix metalloproteinase mediated metabolite of C-reactive protein (CRPM) and two biomarkers of citrullinated vimentin (VICM and anti-MCV) as novel biomarkers of […]

Read publication

The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFRα-mAb treatment in rheumatoid arthritis patients.

February 1, 2019

Clin Exp Rheumatol

Abstract OBJECTIVES Macrophages possess widespread pro-inflammatory, destructive, and remodelling capabilities that can critically contribute to acute and chronic diseases, such as rheumatoid arthritis (RA). Continuous monitoring and measurement of selective counteraction of macrophage activity in patients require a sensitivity and non-invasive marker. We characterised the VICM (citrullinated and MMP degraded vimentin fragment) biomarker by investigating […]

Read publication

Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.

October 1, 2018

Clin Exp Rheumatol

Abstract OBJECTIVES The expanding spectrum of targeted therapies for rheumatoid arthritis (RA) implies a need for development of precision tools for disease assessment reflecting pathobiologic processes. Type IV collagen is an abundant protein of basement membranes, but is also present in the intercellular matrix of the synovial lining layer. We aimed to investigate the association […]

Read publication

IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study.

August 1, 2018

Clin Exp Rheumatol

Abstract OBJECTIVES The objective of this study was to examine the tissue degradation in response to anti-IL6 receptor treatment in rheumatoid arthritis (RA) patients which are anti-TNF-α inadequate responders. METHODS RADIATE was a randomised, double-blinded, placebo-controlled, parallel-group, phase III trial. RA patients with previous inadequate response to anti-TNFα therapy (n=299) were randomly assigned to tocilizumab […]

Read publication

Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients.

June 1, 2018

Clin Exp Rheumatol

Abstract OBJECTIVES This prospective study aimed to use serological biomarkers for evaluation of, connective tissue turnover, in a population of 149 Japanese patients with rheumatoid arthritis (RA). It was aimed to investigate how the connective tissue was affected by treatment at follow-up after 1 year (+/- 6 weeks) with either methotrexate (n=23) alone, or in […]

Read publication

Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis.

February 1, 2018

Clin Exp Rheumatol

Abstract OBJECTIVE Biologics for rheumatoid arthritis (RA) patients with moderate to severe disease may preserve joint function. Matrix metalloproteinase 3 (MMP-3), a key tissue degrading protease, is highly elevated in RA. MMP-3, which measures the total pool of circulating MMP-3 species (cMMP3), is a commonly measured biomarker in rheumatology. The aim was to investigate the […]

Read publication